Last reviewed · How we verify
Gan & Lee insulin glargine followed by Lantus
Gan & Lee insulin glargine followed by Lantus is a Small molecule drug developed by Gan and Lee Pharmaceuticals, USA. It is currently in Phase 1 development.
At a glance
| Generic name | Gan & Lee insulin glargine followed by Lantus |
|---|---|
| Sponsor | Gan and Lee Pharmaceuticals, USA |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gan & Lee insulin glargine followed by Lantus CI brief — competitive landscape report
- Gan & Lee insulin glargine followed by Lantus updates RSS · CI watch RSS
- Gan and Lee Pharmaceuticals, USA portfolio CI
Frequently asked questions about Gan & Lee insulin glargine followed by Lantus
What is Gan & Lee insulin glargine followed by Lantus?
Gan & Lee insulin glargine followed by Lantus is a Small molecule drug developed by Gan and Lee Pharmaceuticals, USA.
Who makes Gan & Lee insulin glargine followed by Lantus?
Gan & Lee insulin glargine followed by Lantus is developed by Gan and Lee Pharmaceuticals, USA (see full Gan and Lee Pharmaceuticals, USA pipeline at /company/gan-and-lee-pharmaceuticals-usa).
What development phase is Gan & Lee insulin glargine followed by Lantus in?
Gan & Lee insulin glargine followed by Lantus is in Phase 1.